At the request of Prostatype Genomics AB, Prostatype Genomics AB equity rights
will be traded on First North Growth Market as from January 23, 2024.
Security name: Prostatype Genomics AB TO3
------------------------------------------
Short name: PROGEN TO3
------------------------------------------
ISIN code: SE0021150794
------------------------------------------
Orderbook ID: 319708
------------------------------------------
Terms:
--------------------------------------------------------------------------------
- 1 warrant of series 3 entitles the holder to subscribe for 1 new share.
The subscription price for the warrant of series 3 will be set at 70
percent of the volume-weighted average price ("VWAP") for the Company's
shares on Nasdaq First North Growth Market during the measurement
period March 14-28, 2024, but at a minimum of SEK 0.01 (corresponding
to the quota value). Warrants of series 3 can be exercised to subscribe
for shares in Prostatype Genomics during the period April 5-19, 2024.
--------------------------------------------------------------------------------
Subscr April 5, 2024 - April 19, 2024
iption
perio
d:
--------------------------------------------------------------------------------
Last April 17, 2024
tradi
ng
day:
--------------------------------------------------------------------------------
This information is distributed at the request of the Certified Adviser,
Carnegie Investment Bank AB (Publ). For further information, please call
Carnegie Investment Bank AB (publ) on +46 (0)8 588 68 570.Nasdaq Stockholm AB: New equity right for trading, Prostatype Genomics AB TO3 (34/24)
© 2024 GlobeNewswire
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.04. | PROSTATYPE GENOMICS AB: Prostatype Genomics announces outcome of exercise of warrants of series 3 (TO3) | ||
| 18.04. | PROSTATYPE GENOMICS AB: Prostatype Genomics announces very strong interim results from long-term follow-up study with Prostatype® in Uppsala | ||
| 17.04. | PROSTATYPE GENOMICS AB: Prostatype Genomics updates on significant progress in the US study with Prostatype® | ||
| 16.04. | PROSTATYPE GENOMICS AB: Prostatype Genomics announces strong positive final results from multicentre study with Prostatype® in Spain | ||
| 02.04. | PROSTATYPE GENOMICS AB: Prostatype Genomics enters into collaboration with Professor E. David Crawford, MD, University of California San Diego, in preparation for the commercial launch of Prostatype® in the United States |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen
Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu
verstehen sein kann.
